GSK Pharma Q4 PAT seen up 15% to Rs 123 cr

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Healthcare company GlaxoSmithKline Pharmaceuticals (GSK Pharma) is set to report a profit after tax (PAT) of Rs 123 crore for the quarter ended December 2010, up 15% as compared to Rs 107.2 crore in same quarter the previous year, according to CNBC-TV18 estimates.

Revenue is seen going up by 22.4% to Rs 510.4 crore from Rs 417 crore (YoY).

Earning before interest, tax, depreciation and amortisation (EBITDA) is likely to go up by 26% to Rs 153 crore from Rs 122 crore (YoY).

Operating profit margin is seen improving marginally at 30% versus 29%.

For the year calendar year 2010, revenues are expected to go up by 14% to Rs 1,891.1 crore from Rs 2,154 crore and EBITDA is likely to go up by 8.8% to Rs 734 crore from Rs 675 crore.

Operating profit margin is seen declining at 34% versus 35.7%.

PAT is seen going up by 8.4% to Rs 555 crore from Rs 512.29 crore (YoY).